Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM Pb Multiple | 0.6x - 0.7x | 0.6x |
| Historical Pb Multiple | 0.6x - 4.4x | 1.4x |
| Fair Value | €1.83 - €2.02 | €1.92 |
| Upside | 30.1% - 43.8% | 36.9% |
| Benchmarks | - | Full Ticker |
| Paul Hartmann AG | - | DB:PHH2 |
| Eckert & Ziegler SE | - | XTRA:EUZ |
| EDAP TMS S.A. | - | DB:EDA |
| Biosynex SA | - | DB:0DL |
| Laboratoires Euromedis Société anonyme | - | DB:61R |
| NanoRepro AG | - | XTRA:NN6 |
| Select Price / Book Ratio | ||||||||
| Benchmark Companies | ||||||||
| PHH2 | EUZ | EDA | 0DL | 61R | NN6 | |||
| DB:PHH2 | XTRA:EUZ | DB:EDA | DB:0DL | DB:61R | XTRA:NN6 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | 13.2% | 12.7% | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | 4.6% | 5.1% | NM- | NM- | -16.7% | NM- | ||
| Latest Twelve Months | 281.6% | 33.4% | 10.2% | -12.1% | 429.3% | 51.4% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 3.1% | 13.4% | -12.8% | 2.4% | 7.2% | -26.1% | ||
| Prior Fiscal Year | 1.2% | 12.2% | -35.0% | 8.0% | -10.9% | -9.6% | ||
| Latest Fiscal Year | 4.5% | 13.5% | -29.7% | -39.7% | 35.0% | -147.2% | ||
| Latest Twelve Months | 4.5% | 13.5% | -29.7% | -37.0% | 58.5% | -89.8% | ||
| Return on Equity | ||||||||
| 5 Year Average Margin | 7.0% | 16.2% | -14.3% | 33.2% | 18.8% | 13.5% | ||
| Prior Fiscal Year | 2.7% | 13.8% | -32.9% | 9.5% | -15.7% | -7.1% | ||
| Latest Twelve Months | 9.8% | 18.0% | -38.9% | -32.1% | 71.1% | -7.8% | ||
| Next Fiscal Year | 5.6% | 20.2% | -64.9% | #NUM! | 6.0% | 3.8% | ||
| Two Fiscal Years Forward | 5.6% | 17.4% | -136.2% | -35.2% | 6.1% | 9.9% | ||
| Current Trading Multiples | ||||||||
| Price / LTM Sales | 0.3x | 3.4x | 0.7x | 0.3x | 0.3x | 5.0x | ||
| Price / LTM EPS | 7.6x | 25.3x | -2.5x | -0.7x | 0.6x | -5.5x | ||
| Price / Book | 0.7x | 4.5x | 1.1x | 0.3x | 0.5x | 0.5x | ||
| Price / Fwd Book | 0.7x | 3.7x | 2.2x | 0.2x | 0.4x | 0.4x | ||
| Low | Mid | High | ||||||
| Benchmark P/B Ratio | 0.3x | 0.7x | 4.5x | |||||
| Historical P/B Ratio | 0.6x | 1.4x | 4.4x | |||||
| Selected P/B Multiple | 0.6x | 0.6x | 0.7x | |||||
| (x) Book Value | 39 | 39 | 39 | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | PHH2 | EUZ | EDA | 0DL | 61R | NN6 | |
| Value of Common Equity | 828 | 1,013 | 45 | 27 | 10 | 18 | |
| (/) Shares Outstanding | 3.6 | 20.8 | 37.4 | 18.7 | 2.8 | 12.6 | |
| Implied Stock Price | 233.00 | 48.60 | 1.20 | 1.42 | 3.51 | 1.41 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 233.00 | 48.60 | 1.20 | 1.42 | 3.51 | 1.41 | |
| Trading Currency | EUR | EUR | EUR | EUR | EUR | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |